AZD-1386

DB15333InvestigationalSmall molecule

AZD-1386 is under investigation in clinical trial NCT00945178 (Double-blind Placebo-controlled 2-part Study Assessing the Safety, Tolerability and PK of AZD1386 in Healthy Volunteers).

Mechanism: Pharmacologically active on Transient receptor potential cation channel subfamily V member 1
Curator reviewed
Formula / weight: C₂₁H₂₃F₂N₃O · 371.432 g/mol (avg)
Code names: AZD-1386

Resolves to

Compound

UNII210323T9CPCAS942937-80-6

Structure

InChIKeyFPGNKXCEPARJDI-ZDUSSCGKSA-NSMILESC[C@H](NC(=O)CN1C=NC2=C1C(F)=C(F)C=C2)C1=CC=C(C=C1)C(C)(C)C

Targets

Q8NER1TRPV1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

10Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with AZD-1386, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account